In its seminal trial, the addition of trastuzumab to chemotherapy saw an increase in median survival from 20.3 months to 25.1 months (p = 0.046) (5), revolutionizing the treatment of HER2+ BC. The gene discussed is ERBB2; the disease is breast cancer.